

# MEDICAL TECHNOLOGY ACQUISITION OPPORTUNITY

## STB-FAST™ Wound Care Hemostatic Technology

### The Opportunity

Acquisition or licensing of Intellectual Property Assets associated with the production and marketing of the **STB-FAST™** (Fibrin Adhesive STat) hemostatic technology. Seller is open to flexible deal structuring.

### The Need

Hemostats, designed to treat minor surgical bleeding, are currently unfit for use in massive trauma or internal bleeding situations. Currently, there are no meaningful market solutions involving highly effective, bioabsorbable, hemostatic dressings or compounds that effectively control life-threatening hemorrhaging.

### The Technology

The STB-FAST™ patents cover the process by which hemostatic agents (fibrinogen and thrombin) are combined and attached to a bioabsorbable backing material that has negligible catalyzed conversion of fibrinogen to fibrin. The flexibility of this process enables multiple applications with the same product, generating a lower overall cost for the end user. Dressings can be cut to suit a specific use while maintaining effectiveness.

In addition to wound dressings, the proprietary processes may be used to produce liquids, putties, or rods for vascular or endoscopic use. (See chart below). Material is stable in a controlled environment for up to 2 years.

*“...a superior hemostatic efficacy of the FAST dressing that surpasses any other known hemostatic agent. To our knowledge, FAST is the only dressing capable of stopping any type of life-threatening hemorrhage (arterial, venous, or mixed solid organ)...”* -- US Army Institute of Surgical Research

### Market Readiness

- 2025 Projected market for hemostatic agents is expected to be \$5.44B (Fortune Business Insights, 2019)
- Independently tested and validated by US Army Institute of Surgical Research
- Manufacturing process is portable, simple, and customizable allowing for efficient entry into new markets
- Material is biodegradable potentially posing fewer regulatory hurdles to FDA approval

### Potential Areas of Market Disruption

- Customizable to a wide range of hemorrhagic events
- Low production costs due to high yields and use of F1 paste for fibrinogen source (greater than 95% purity)
- Long shelf life in controlled environment

Product	Fast® Dressing	Fast® Putty	Fast® Rod	Fast® Vascular Access	Fast® Kittner
Description	4"x4" Wound dressing	Malleable putty	Freeze-dried, ready to use syringes	Arterial access point	Endoscopy kittner
Resorbable backing	✓				✓
Trauma	✓	✓	✓		
Surgery	✓	✓	✓	✓	✓
Mild Bleeding				✓	✓
Moderate Bleeding	✓	✓	✓	✓	✓
Severe Bleeding	✓				

**Matthew Latimer**  
 Managing Director & General Counsel  
 (206) 914-5484  
[mlatimer@actcapitaladvisors.com](mailto:mlatimer@actcapitaladvisors.com)



**Dan Nicklaus**  
 Vice President  
 (206) 920-5832  
[dnicklaus@actcapitaladvisors.com](mailto:dnicklaus@actcapitaladvisors.com)


# MEDICAL TECHNOLOGY ACQUISITION OPPORTUNITY

## STB-FAST™ Wound Care Hemostatic Technology

"...[I]n our opinion, [the STB-FAST Technology] is a giant leap forward in hemorrhage control therapy which could benefit both prehospital and in-hospital (surgical) care of combat casualties where no other means is practical..." -- US Army Institute of Surgical Research

### Assets Available for Purchase

- STB-FAST™ Patent Portfolio
  - 3 Issued patents for STB dressing
  - 2 Notifications given
  - 4 Pending patents in the US
- Rights to Purification Trade Secrets
- Trademarks
- Specialized Production Equipment



Graphic credits: Medical library (doctorlib.info)

### Purification Trade Secret Process Rights

The offered technology includes a proprietary Fibrinogen purification process used to produce a key component of the STB-FAST™ products at relatively low cost. This process:

- Employs conventional processing steps and equipment
- Uses less expensive Fraction 1 (F1) paste to produce fibrinogen
- Achieves high yields
- Produces excellent Purity (>95%)

### Indications of Interest

If you are interested in exploring this opportunity, please execute the Non-Disclosure Agreement or contact Dan Nicklaus or Matt Latimer for further information. Seller is open to various deal structures, including, without limitation, assets sales, licensing arrangements, joint ventures, etc. Assets may be purchased as a portfolio or individually. NDA may be found at: <https://actcapitaladvisors.com/2021/07/medical-technology-acquisition-opportunity/>

**Deadline for Indications of Interest:**

**September 17th, 2021**

**For More Information Contact:**

**Matthew Latimer**  
Managing Director & General Counsel  
(206) 914-5484  
[mlattimer@actcapitaladvisors.com](mailto:mlattimer@actcapitaladvisors.com)



**Dan Nicklaus**  
Vice President  
(206) 920-5832  
[dnicklaus@actcapitaladvisors.com](mailto:dnicklaus@actcapitaladvisors.com)